Ypsomed Holding AG: Business Overview, Financials & Competitive Analysis
Ypsomed Holding AG scores 8/10 on the AskCyborg Cyborg Score (Strong). Ypsomed is a high-growth, cash-generative medical device compounder with unprecedented capacity expansion into a secular growth market, supported by a fortress balance sheet. Trailing twelve month revenue for Ypsomed is $925M, with 2024 revenue of 748.87 million, an increase of 36.54% compared to the previous year. Strong balance sheet.
What is Ypsomed Holding AG's industry? Ypsomed Holding AG (ypsomed.com) operates in Medical Devices & Equipment - Injectable Drug Delivery Systems. AskCyborg classifies Ypsomed Holding AG under Medical Devices & Equipment - Injectable Drug Delivery Systems in its company registry.
Ypsomed Holding AG develops, manufactures, and sells injection and infusion systems for safe and simple self-medication. The company operates across two primary business segments—Delivery Systems (serving pharmaceutic...
Cyborg Score thesis
Ypsomed is a high-growth, cash-generative medical device compounder with unprecedented capacity expansion into a secular growth...
Read the full analyst-debate transcript →Get the Latest Ypsomed Holding AG Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeYpsomed Holding AG Overview
Pro stress-test →Ypsomed Holding AG develops, manufactures, and sells injection and infusion systems for safe and simple self-medication. The company operates across two primary business segments—Delivery Systems (serving pharmaceutical/biotech partners) and Diabetes Care (consumer/patient focused)—positioning itself as a critical infrastructure provider for the rapidly expanding injectable drug market, particularly in diabetes and GLP-1 therapies.
Strategic Profile
Pro stress-test →Ypsomed intends to focus on expanding its leading position in Delivery Systems and is examining strategic options for the Diabetes Care business area. The company is investing CHF 1.5 billion to nearly triple capacity to 1 billion devices by early next decade, with new sites in Germany, China, and the U.S. This aggressive expansion capitalizes on booming demand for autoinjectors as major pharma scales obesity and diabetes treatments.
Competitive Landscape
Pro stress-test →SHL Medical is a competitor of Ypsomed, a private equity-backed company in Zug, Switzerland. Other implicit competitors include larger medical device conglomerates and specialty pharma device partners like Gerresheimer and Schott Pharma. Ypsomed's competitive advantage stems from scale, integrated manufacturing footprint, and proven ability to customize for major pharma partners, creating high switching costs.
Industry Context
Ypsomed Holding AG operates in Medical Devices & Equipment - Injectable Drug Delivery Systems.
Key facts
Founded: 1984 · Headquarters: Burgdorf, Switzerland · Employees: 2644 · Revenue: $925M · Market cap: $5.76B